PBYI
NASDAQ · Biotechnology
Puma Biotechnology Inc
$8.91
+0.79 (+9.73%)
Open$8.15
Previous Close$8.12
Day High$9.40
Day Low$8.12
52W High$8.75
52W Low$3.05
Volume—
Avg Volume277.0K
Market Cap423.99M
P/E Ratio17.39
EPS$0.48
SectorBiotechnology
Analyst Ratings
Strong Sell
6 analysts
Price Target
-38.8% upside
Current
$8.91
$8.91
Target
$5.45
$5.45
$2.99
$5.45 avg
$6.80
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 248.58M | 248.45M | 42.11M |
| Net Income | 33.86M | 30.46M | 7.89M |
| Profit Margin | 13.6% | 12.9% | 18.7% |
| EBITDA | 52.51M | 49.86M | 13.15M |
| Free Cash Flow | — | — | 4.76M |
| Rev Growth | +0.1% | +0.1% | +7.6% |
| Debt/Equity | 0.17 | 0.17 | 0.46 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $246.04 | +0.89% | 118.6 | 430.95B |
| AMGN | Amgen Inc | $410.95 | +1.51% | 25.1 | 219.39B |
| GILD | Gilead Sciences Inc | $133.21 | +1.80% | — | 165.85B |
| VRTX | Vertex Pharmaceuticals Inc | $496.07 | +2.49% | 28.3 | 124.51B |
| REGN | Regeneron Pharmaceuticals | $784.36 | +1.59% | 18.4 | 79.53B |
| ALNY | Alnylam Pharmaceuticals Inc | $219.20 | +1.43% | 35.2 | 28.41B |